Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

PARP-1 inhibition sensitizes temozolomide-treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity andPTENproficiency

Texto completo
Autor(es):
Montaldi, Ana P. [1] ; Lima, Sarah C. G. [1] ; Godoy, Paulo R. D. V. [1] ; Xavier, Danilo J. [1] ; Sakamoto-Hojo, Elza T. [1, 2]
Número total de Autores: 5
Afiliação do(s) autor(es):
[1] Univ Sao Paulo, USP, Fac Philosophy Sci & Letters Ribeirao Preto, Dept Biol, 3900 Bandeirantes Ave, BR-14040901 Ribeirao Preto, SP - Brazil
[2] Univ Sao Paulo, USP, Ribeirao Preto Med Sch, Dept Genet, BR-14049900 Ribeirao Preto, SP - Brazil
Número total de Afiliações: 2
Tipo de documento: Artigo Científico
Fonte: ONCOLOGY REPORTS; v. 44, n. 5, p. 2275-2287, NOV 2020.
Citações Web of Science: 0
Resumo

Information on the mechanisms that are associated with tumor resistance has the potential to provide the fundamental basis for novel therapeutic strategies. In glioblastoma (GBM), predictive biomarkers of cellular responses to temozolomide (TMZ) combined with poly-ADP-ribose polymerase inhibitor (PARPi) remain largely unidentified. In this context, the influence of MGMT (O-6-methylguanine DNA methyltransferase) and PTEN (phosphatase and tensin homologue deleted on chromosome ten) has been studied in addition to the occurrence of synthetic lethality involving PTEN and PARPi. The present study investigated whether PARP-1 inhibition by NU1025 may increase the cytotoxicity of TMZ-induced lesions in GBM cells, and whether these mechanisms can be influenced by MGMT andPTENstatus. The impact ofPTENdeficiency in repair pathways, and the effects of PARP-1 inhibition andPTENsilencing, in terms of synthetic lethality, were also assessed. NU1025 combined with TMZ effectively sensitized TMZ-resistant cells (T98GPTEN-mutated and LN18PTEN-wild-type) and TMZ-sensitive cells (U251MGPTEN-mutated), in contrast to NU1025 alone. However, the sensitizing effects were not observed in U87MG (PTEN-mutated) cells, suggesting that specific genetic alterations may influence the response to drug treatment. The sensitizing effects occurred independently of MGMT activity, which was evaluated in O6-BG-treated cells.PTENsilencing using small interfering (si)RNA did not sensitizePTEN-proficient cells to TMZ + NU1025, or NU1025 alone, indicating an absence of synthetic lethality. The responses to TMZ + NU1025 involved antiproliferative activity, G2/M arrest, double strand breaks and the induction of apoptosis. Following 20 days of recovery after three consecutive days of TMZ treatment, TMZ-resistant cells were observed. However, when TMZ was combined with NU1025, the viability of T98G and LN18 cells was extremely decreased, indicating a lethal drug combination. Therefore, independently of MGMT proficiency andPTENstatus, TMZ combined with PARPi may be a promising strategy that can be used to overcome TMZ acquired resistance in GBM cells. (AU)

Processo FAPESP: 16/17862-3 - Avaliação da influência do reparo MGMT nas respostas de linhagens de glioblastoma à associação de TMZ ao inibidor de PARP-1 (NU1025)
Beneficiário:Sarah Caroline Gomes de Lima
Linha de fomento: Bolsas no Brasil - Iniciação Científica
Processo FAPESP: 13/12033-0 - "inibição de reparo do dna em linhagens de glioblastoma visando uma possível aplicação como estratégia terapêutica"
Beneficiário:Ana Paula de Lima Montaldi
Linha de fomento: Bolsas no Brasil - Pós-Doutorado
Processo FAPESP: 13/09352-7 - Instabilidade genômica e vias de sinalização molecular envolvendo respostas a danos e reparo do DNA em doenças humanas
Beneficiário:Elza Tiemi Sakamoto Hojo
Linha de fomento: Auxílio à Pesquisa - Regular